---
title: "Venus Medtech Outlines Board and Committee Roles to Strengthen Governance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286565659.md"
description: "Venus Medtech (Hangzhou) Inc. has detailed its board composition, emphasizing independent oversight in governance. The board includes executive, non-executive, and independent non-executive directors, with independent directors chairing key committees. This structure aims to enhance corporate governance and reassure investors about oversight mechanisms. Venus Medtech is a medical technology company listed in Hong Kong under stock code 2500, focusing on innovative medical devices."
datetime: "2026-05-15T12:10:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286565659.md)
  - [en](https://longbridge.com/en/news/286565659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286565659.md)
---

# Venus Medtech Outlines Board and Committee Roles to Strengthen Governance

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ).

Venus Medtech (Hangzhou) Inc. has disclosed the current composition of its board of directors, detailing the mix of executive, non-executive, and independent non-executive directors and their respective responsibilities. The announcement clarifies the leadership structure across key governance committees, with independent directors chairing the audit, remuneration and assessment, and nomination committees, underscoring the company’s emphasis on oversight and corporate governance.

Chairman and independent non-executive director Ting Yuk Anthony Wu serves as a member or chair of several committees, while fellow independent directors Chi Wai Suen and John Junhua Gu hold chair and member roles across the audit, remuneration, and nomination bodies. This structure signals a strong role for independent oversight in the company’s governance framework, which may reassure investors and other stakeholders about checks and balances at the board level.

**More about Venus Medtech (Hangzhou), Inc. Class H**

Venus Medtech (Hangzhou) Inc. is a medical technology company based in the People’s Republic of China and listed in Hong Kong under stock code 2500. The company operates in the healthcare sector, focusing on innovative medical devices, and is governed by a board comprising executive, non-executive, and independent non-executive directors to oversee strategy and governance.

**Average Trading Volume:** 1,173,553

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$701.2M

### Related Stocks

- [02500.HK](https://longbridge.com/en/quote/02500.HK.md)

## Related News & Research

- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [13:41 ETUT Haslam Marks Decade in Major International Ranking's Top Five U.S. Public Schools](https://longbridge.com/en/news/286804132.md)
- [Tencent Music completes $2.6 billion acquisition of podcast platform Ximalaya](https://longbridge.com/en/news/286841981.md)
- [UAE among first globally to approve new obesity, hypertension treatments](https://longbridge.com/en/news/286707352.md)
- [15:45 ET"Lean" Strengthens Saudi Arabia's Presence in Global Digital Health and Precision Medicine Ecosystems](https://longbridge.com/en/news/286811787.md)